Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11945868 Antibody molecules to CD138 and uses thereof

Patent 11945868 was granted and assigned to Visterra Inc. on April, 2024 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

0

Patent attributes

Patent Applicant

0

Current Assignee

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Bharat Chaganty0

Boopathy Ramakrishnan0

Karthik Viswanathan0

Hedy Adari-Hall0

Zachary Shriver0

James R. Myette0

Date of Patent

April 2, 2024

0

Patent Application Number

161498540

Date Filed

October 2, 2018

0

Patent Citations

US Patent 9803021 CD138-targeted interferon demonstrates potent apoptotic and anti-tumor activities

0

US Patent 9862772 Compositions and methods

0

US Patent 9964542 Bladder cancer detection composition, kit, and associated methods

0

US Patent 10117932 Uses of immunoconjugates targeting CD138

0

US Patent 10975158 CD138-targeted interferon demonstrates potent apoptotic and anti-tumor activities

0

US Patent 10662250 Humanized monoclonal antibody specific to syndecan-1

0

US Patent 8840898 Immunoconjugates targeting syndecan-1 expressing cells and use thereof

0

US Patent 9221914 Agents targeting CD138 and uses thereof

0

...

Patent Primary Examiner

Nelson B Moseley, II

0

CPC Code

0

0

0

0

0

0

0

0

...

Patent abstract

Antibody molecules that specifically bind to CD138 are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as multiple myeloma.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11945868 Antibody molecules to CD138 and uses thereof

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.